In Raising Biotech's first season revealed the complexities and strategic decisions biotech startups must navigate as they grow their companies and advance their platforms. One of the most crucial choices involves determining the right pathway to secure the capital and support needed for long-term success. The CEOs featured this season shed light on how companies weigh the benefits of partnerships, IPOs, and acquisitions, each decision closely tied to their missions and visions for the future.
1. Partnerships to fuel growth and expertise
Partnerships often represent an early and strategic way for biotech companies to scale their platforms and clinical operations while accessing expertise and infrastructure they may not possess internally. Companies like eGenesis, Ochre Bio, and Empress Therapeutics exemplify how partnerships can be leveraged for both financial and strategic gain.
Mike Curtis of eGenesis discussed how crucial partnerships are for advancing their work in xenotransplantation. The company’s approach to developing genetically modified pig organs for human transplantation requires substantial expertise in manufacturing, logistics, and regulatory compliance. Curtis highlighted how aligning with larger pharmaceutical firms or healthcare companies is essential for scaling up their operations and launching global clinical trials, particularly as they prepare to test their technology in the U.S. and Japan. Partnerships, therefore, become a bridge to the necessary infrastructure and resources that eGenesis needs to expand its reach and make a meaningful impact on the organ shortage crisis.
Jack O’Meara of Ochre Bio highlighted the importance of partnerships for scaling their innovative “liver ICU” platform. By focusing on human liver models rather than animal models, Ochre Bio is taking a unique approach that could benefit from collaborations with pharmaceutical companies to support their clinical trials. O’Meara sees partnerships as a key avenue to access resources and expertise that can accelerate the company’s development plans, allowing them to advance their drug candidates and expand their reach in liver disease treatment.
Similarly, Jason Park of Empress Therapeutics emphasized the importance of partnerships as a way to accelerate the development of their small molecule drug candidates. As Empress continues to innovate within the biotech space by utilizing human-compatible chemistry, partnerships with established pharma companies could provide the infrastructure needed to test and scale their candidates. Park made it clear that while Empress has raised significant funding, strategic partnerships will be essential for expanding their clinical reach and navigating regulatory pathways faster.
2. IPOs to generate scale while maintaining independence
For some biotech startups, going public is a strategic move that provides the necessary capital to independently drive clinical and commercial growth. Although these companies have not yet reached the stage of initiating an IPO, Synchron, eGenesis, Ochre Bio and Alltrna discussed how IPOs can align with their long-term missions, offering a clear pathway to raise substantial funds while maintaining control over their scientific direction.
Synchron, on the other hand, sees an IPO as a key step for its growth trajectory. Dr. Oxley mentioned that while Synchron is currently focused on raising another $50 to $75 million for FDA approval, the company envisions a larger round of $200 to $250 million—likely through public markets—to scale their operations and take their BCI technology to the next level. For Synchron, an IPO is not just about raising capital; it’s about achieving the independence needed to fully explore and expand its neurotech platform.
Mike Curtis of eGenesis also noted that an IPO is a strong option as the company scales up. With xenotransplantation being a high-risk, high-reward field, Curtis explained that going public could provide the large-scale capital necessary to expand operations and manage the complex logistics of bringing genetically modified organs to market. By tapping into the public markets, eGenesis aims to leverage the financial muscle needed for global expansion while retaining a level of strategic independence.
Jack O’Meara of Ochre Bio also discussed the potential for an IPO as the company advances its clinical trials. After securing Series A funding and relocating to the U.S. to tap into a larger investor base, Ochre Bio is strategically positioning itself for growth. An IPO would allow the company to scale its liver-focused platform and fund further clinical trials, aligning with O’Meara’s vision to address the global burden of liver disease while maintaining the company’s autonomy.
Michelle Werner of Alltrna highlighted that, while the company is still in the early stages of clinical planning, an IPO is always a future consideration. As Alltrna continues to build out its tRNA platform targeting a vast array of genetic diseases, going public could provide the capital needed to expand and commercialize its pipeline across multiple indications while allowing the company to maintain strategic control. Werner’s background in oncology and experience with public markets makes her well placed to navigate this possibility, ensuring Alltrna is structured for scale and flexibility as it moves forward.
3. Acquisition for faster scale-up
Acquisition remains a clear option for some biotech companies aiming to leverage the resources of larger pharmaceutical firms to bring their innovations to market faster and at scale. Several CEOs this season acknowledged the possibility of acquisitions, particularly for those focused on niche areas where integration with established players could significantly accelerate development.
Jay Lichter of Arialys Therapeutics made it clear that while the company could remain independent as it focuses on orphan conditions like anti-NMDA receptor encephalitis, an acquisition would be the preferred path if they decide to target broader indications such as schizophrenia. For Arialys, being acquired by a larger pharmaceutical company would provide the infrastructure and capital necessary to navigate the complex clinical trials required for such large indications. Lichter sees acquisition as a way to maximize the impact of Arialys’s platform, aligning with his mission to expand the company’s capabilities and reach a broader patient base.
Balancing mission and strategy
The biotech leaders featured in Raising Biotech exemplify how mission-driven companies carefully evaluate partnerships, IPOs, and acquisitions based on their long-term goals and the scale of their ambitions. For some, partnerships provide the necessary resources to advance clinical development without sacrificing independence, while others see IPOs as a means to access large-scale capital while maintaining control over their innovations. Acquisitions, meanwhile, are viewed as an opportunity to maximize the reach and impact of a platform by leveraging the infrastructure and capabilities of larger pharmaceutical players.
What remains consistent is the need for alignment between a company’s scientific mission and its business strategy. Whether it’s Synchron’s phased approach to financing and market entry, Ochre Bio’s dual strategy of partnerships and IPOs for expansion, or Arialys’s readiness for acquisition to broaden its impact, the choices these biotech startups make are deeply rooted in their long-term visions for patient care and medical innovation.
For biotech startups, the path to success involves much more than scientific breakthroughs. It requires a careful balance of clinical ambition, regulatory strategy, and financial planning. As Season 1 of Raising Biotech reveals, the choice between partnerships, IPOs, and acquisitions is not just a business decision; it’s a strategic alignment with a company’s core mission and vision for the future.